Login to Your Account



Clinic Roundup


Friday, June 10, 2011
Neoprobe Corp., of Dublin, Ohio, said full results from its NEO3-05 study demonstrated that Lymphoseek (99mTc-tilmanocept) met all primary and secondary endpoints in intraoperative lymphatic mapping procedures. Study subjects yielded a total of 215 lymph nodes stained with vital blue dye and, of those, Lymphoseek detected 210, for a concordance rate of 97.67 percent, hitting statistical significance (p < 0.0001).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription